GRI Bio, Inc. (GRI)
Nasdaq: GRI · Pharmaceutical Preparations · La Jolla, CA · filing with the SEC since 2020
Who owns GRI Bio, Inc.
As filed with the SECHolders of 5% or more
0
No Schedule 13D or 13G naming this company is on file.
Directors and officers
7
report now, of 14 people on the record since 2021. Their holdings as a group are not read here.
Institutions as a whole
n/a
The record does not read the share held by managers that file Form 13F, so none is printed and no split of the rest is estimated. What it holds is the 0 named at left.
Holders of 5% or moreshare of the class, as filed
Mitchell P. Kopin
SCHEDULE 13G/A · filed Aug 13, 2026 · Common stock, par value $0.0001 per share · reported falling below 5%, from 5.9% in May 13, 2026
Lincoln Alternative Strategies LLC
SCHEDULE 13G/A · filed Feb 10, 2026 · Common stock, par value $0.0001 per share · reported falling below 5%, from 11.8% in Dec 29, 2025
What GRI reports owning in othersstakes of 5% or more, and other ties
GRI Bio, Inc. reports no stake in another company in the record.
Insider tradesForm 4
0sales
0purchases
0sales on a scheduled plan
0people selling
$0sold, in dollars
$0bought, in dollars
Open-market trades on Form 4 from Sep 30, 2025 to Sep 30, 2026. A scheduled plan is a selling program set in advance under SEC rule 10b5-1. The trades are listed as filed and do not feed the grade.
By calendar yearSoldBought
2021 runs to Sep 30, 2026. Dollars as filed, summed by the transaction date.
People who traded in the window
No one on the roster filed an open-market trade in the window.